ImmunoPrecise Antibodies Ltd. (IPA.V)

17.15 +0.27 (+1.60%) At close: 3:59PM EST

ImmunoPrecise Antibodies Ltd.

4837 Amber Valley Parkway
Suite 11
Fargo, ND 58104
United States
701 353 0022
http://www.immunoprecise.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. James S. Kuo M.B.A., M.D.	Independent Chairman	N/A	N/A	1965
Dr. Jennifer Lynne Bath Ph.D.	CEO, Pres & Director	1.06M	N/A	N/A
Ms. Lisa Helbling	Chief Financial Officer	438.46k	N/A	N/A
Dr. Yasmina Noubia Abdiche Ph.D.	Chief Scientific Officer	30.49k	N/A	N/A
Dr. Stefan Lang	Chief Bus. Officer	219.58k	N/A	N/A
Mr. David E. Orton	Chief Operating Officer	N/A	N/A	N/A
Ms. Lauren Smith	VP of Marketing and Sales	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.

Corporate Governance

ImmunoPrecise Antibodies Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.